HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
20:@0.083944:0.033217:0.104640:0.033217:0.104640:0.013052:0.083944:0.013052:0.010348:0.010348
TREATMENT AppROACHEs:@0.397030:0.032906:0.624375:0.032906:0.624375:0.013617:0.397030:0.013617:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
Cholestyramine:@0.076190:0.086287:0.204198:0.086287:0.204198:0.067956:0.076190:0.067956:0.013103:0.010079:0.010751:0.004032:0.010751:0.007392:0.005040:0.009743:0.005376:0.011087:0.015791:0.004032:0.010079:0.010751
Cholestyramine  works  by binding bile acids in the  in-:@0.076190:0.102817:0.480942:0.102817:0.480942:0.087035:0.076190:0.087035:0.012292:0.009223:0.009903:0.003024:0.009827:0.005866:0.005125:0.008104:0.004551:0.010326:0.014182:0.003024:0.009223:0.009827:0.004188:0.002903:0.012564:0.009903:0.004551:0.007590:0.005866:0.004188:0.002903:0.010311:0.008104:0.007106:0.010311:0.003024:0.009223:0.010357:0.003024:0.009223:0.010175:0.007106:0.010311:0.003024:0.003024:0.009827:0.007106:0.010326:0.009782:0.003024:0.010357:0.005866:0.007106:0.003024:0.009223:0.007106:0.005125:0.009223:0.009827:0.004188:0.002903:0.003024:0.009223:0.005020
testine  and  reducing  the  endogenous  bile-acid pool. :@0.076190:0.117180:0.485145:0.117180:0.485145:0.101397:0.076190:0.101397:0.005125:0.009827:0.005866:0.005125:0.003024:0.009223:0.009827:0.004188:0.002646:0.010326:0.009223:0.010357:0.004188:0.002646:0.004551:0.009827:0.010357:0.009192:0.009782:0.003024:0.009223:0.010175:0.004188:0.002646:0.005125:0.009223:0.009827:0.004188:0.002646:0.009827:0.009223:0.010357:0.009903:0.010175:0.009827:0.009223:0.009903:0.009192:0.005866:0.004188:0.002646:0.010311:0.003024:0.003024:0.009827:0.005020:0.010326:0.009782:0.003024:0.010357:0.006849:0.010311:0.009903:0.009903:0.003024:0.004188:0.004188
Cholestyramine is not absorbed systemically  and is :@0.076190:0.131542:0.485130:0.131542:0.485130:0.115760:0.076190:0.115760:0.012292:0.009223:0.009903:0.003024:0.009827:0.005866:0.005125:0.008104:0.004551:0.010326:0.014182:0.003024:0.009223:0.009827:0.010100:0.003024:0.005866:0.010100:0.009223:0.009903:0.005125:0.010100:0.010326:0.010311:0.005866:0.009903:0.004551:0.010311:0.009827:0.010357:0.010100:0.005866:0.008104:0.005866:0.005125:0.009827:0.014182:0.003024:0.009782:0.010326:0.003024:0.003024:0.008104:0.004188:0.005927:0.010326:0.009223:0.010357:0.010100:0.003024:0.005866:0.004188
therefore very safe. Gastro-intestinal side effects in the :@0.076190:0.145905:0.485145:0.145905:0.485145:0.130122:0.076190:0.130122:0.005125:0.009223:0.009827:0.004551:0.009827:0.004747:0.009903:0.004551:0.009827:0.005443:0.008376:0.009827:0.004551:0.008104:0.005458:0.005866:0.010326:0.004747:0.009827:0.004188:0.005458:0.013184:0.010326:0.005866:0.005125:0.004551:0.009903:0.005020:0.003024:0.009223:0.005125:0.009827:0.005866:0.005125:0.003024:0.009223:0.010326:0.003024:0.005458:0.005866:0.003024:0.010357:0.009827:0.005458:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.005458:0.003024:0.009223:0.005458:0.005125:0.009223:0.009827:0.004188
form of nausea, bloating and constipation are frequent :@0.076190:0.160267:0.485160:0.160267:0.485160:0.144485:0.076190:0.144485:0.004747:0.009903:0.004551:0.014182:0.004052:0.009903:0.004747:0.004052:0.009223:0.010326:0.009192:0.005866:0.009827:0.010326:0.004188:0.004067:0.010311:0.003024:0.009903:0.010326:0.005125:0.003024:0.009223:0.010175:0.004067:0.010326:0.009223:0.010357:0.004067:0.009782:0.009903:0.009223:0.005866:0.005125:0.003024:0.010311:0.010326:0.005125:0.003024:0.009903:0.009223:0.004067:0.010326:0.004551:0.009827:0.004067:0.004747:0.004551:0.009827:0.010311:0.009192:0.009827:0.009223:0.005125:0.004188
and  many  patients  tolerate  cholestyramine  poorly. :@0.076190:0.174630:0.485115:0.174630:0.485115:0.158847:0.076190:0.158847:0.010326:0.009223:0.010357:0.004188:0.006713:0.014182:0.010326:0.009223:0.008104:0.004188:0.006713:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188:0.006713:0.005125:0.009903:0.003024:0.009827:0.004551:0.010326:0.005125:0.009812:0.004188:0.006713:0.009782:0.009223:0.009903:0.003024:0.009827:0.005866:0.005125:0.008104:0.004551:0.010326:0.014182:0.003024:0.009223:0.009827:0.004188:0.006713:0.010311:0.009903:0.009903:0.004551:0.003024:0.008104:0.004188:0.004188
Cholestyramine may also interfere significantly with the :@0.076190:0.188993:0.485145:0.188993:0.485145:0.173210:0.076190:0.173210:0.012292:0.009223:0.009903:0.003024:0.009827:0.005866:0.005125:0.008104:0.004551:0.010326:0.014182:0.003024:0.009223:0.009827:0.004914:0.014182:0.010326:0.008104:0.004914:0.010326:0.003024:0.005866:0.009903:0.004914:0.003024:0.009223:0.005125:0.009827:0.004551:0.004747:0.009827:0.004551:0.009827:0.004899:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009782:0.010326:0.009223:0.005125:0.003024:0.008104:0.004914:0.012564:0.003024:0.005125:0.009223:0.004914:0.005125:0.009223:0.009827:0.004188
absorption of other medications and should be dosed :@0.076190:0.203355:0.485160:0.203355:0.485160:0.187572:0.076190:0.187572:0.010326:0.010311:0.005866:0.009903:0.004551:0.010311:0.005125:0.003024:0.009903:0.009223:0.005488:0.009903:0.004747:0.005488:0.009903:0.005125:0.009223:0.009827:0.004551:0.005473:0.014182:0.009827:0.010357:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.005488:0.010326:0.009223:0.010357:0.005488:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.005488:0.010311:0.009827:0.005488:0.010357:0.009903:0.005866:0.009827:0.010357:0.004188
well apart from other medications. :@0.076190:0.217718:0.333048:0.217718:0.333048:0.201935:0.076190:0.201935:0.012564:0.009827:0.003024:0.003024:0.004188:0.010326:0.010311:0.010326:0.004551:0.005125:0.004188:0.004747:0.004551:0.009903:0.014182:0.004188:0.009903:0.005125:0.009223:0.009827:0.004551:0.004188:0.014182:0.009827:0.010357:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.004188
Cholestyramine should not be used in patients with hy-:@0.090478:0.232080:0.480987:0.232080:0.480987:0.216298:0.090478:0.216298:0.011989:0.008920:0.009601:0.002721:0.009525:0.005564:0.004823:0.007801:0.004248:0.010024:0.013879:0.002721:0.008920:0.009525:0.004883:0.005564:0.008920:0.009601:0.008890:0.002721:0.010054:0.004883:0.008920:0.009601:0.004823:0.004883:0.010009:0.009525:0.004883:0.008890:0.005564:0.009525:0.010054:0.004883:0.002721:0.008920:0.004883:0.010009:0.010024:0.004823:0.002721:0.009525:0.008920:0.004823:0.005564:0.004883:0.012262:0.002721:0.004823:0.008920:0.004883:0.008920:0.007801:0.005020
pertriglyceridaemia as it may increase triglycerides further. :@0.076190:0.246443:0.485130:0.246443:0.485130:0.230660:0.076190:0.230660:0.010009:0.009525:0.004248:0.004823:0.004248:0.002721:0.009873:0.002721:0.007801:0.009480:0.009525:0.004248:0.002721:0.010054:0.010024:0.009525:0.013879:0.002721:0.010024:0.003190:0.010024:0.005564:0.003190:0.002721:0.004823:0.003190:0.013879:0.010024:0.007801:0.003190:0.002721:0.008920:0.009480:0.004248:0.009525:0.010024:0.005564:0.009525:0.003190:0.004823:0.004248:0.002721:0.009873:0.002721:0.007801:0.009480:0.009525:0.004248:0.002721:0.010054:0.009525:0.005564:0.003190:0.004445:0.008890:0.004248:0.004823:0.008920:0.009525:0.004248:0.004188:0.004188
The main indications for cholestyramine are statin intoler-:@0.076190:0.260805:0.480987:0.260805:0.480987:0.245023:0.076190:0.245023:0.006138:0.008920:0.009525:0.004974:0.013879:0.010024:0.002721:0.008920:0.004974:0.002721:0.008920:0.010054:0.002721:0.009480:0.010024:0.004823:0.002721:0.009601:0.008920:0.005564:0.004974:0.004445:0.009601:0.004248:0.004974:0.009480:0.008920:0.009601:0.002721:0.009525:0.005564:0.004823:0.007801:0.004248:0.010024:0.013879:0.002721:0.008920:0.009525:0.004974:0.010024:0.004248:0.009525:0.004974:0.005564:0.004823:0.010024:0.004823:0.002721:0.008920:0.004974:0.002721:0.008920:0.004823:0.009601:0.002721:0.009525:0.004248:0.005020
ance or inadequate response to maximal doses of statins. :@0.076190:0.275168:0.485130:0.275168:0.485130:0.259385:0.076190:0.259385:0.010024:0.008920:0.009480:0.009525:0.003734:0.009601:0.004248:0.003734:0.002721:0.008920:0.010024:0.010054:0.009525:0.010009:0.008890:0.010024:0.004823:0.009525:0.003734:0.004248:0.009525:0.005564:0.010009:0.009601:0.008920:0.005564:0.009525:0.003734:0.004823:0.009601:0.003734:0.013879:0.010024:0.006955:0.002721:0.013879:0.010024:0.002721:0.003734:0.010054:0.009601:0.005564:0.009525:0.005564:0.003734:0.009601:0.004445:0.003734:0.005564:0.004823:0.010024:0.004823:0.002721:0.008920:0.005564:0.004188:0.004188
Ezetimibe has become the drug of choice for these indi-:@0.076190:0.289530:0.480942:0.289530:0.480942:0.273748:0.076190:0.273748:0.007801:0.006123:0.009525:0.004823:0.002721:0.013879:0.002721:0.010009:0.009525:0.004989:0.008920:0.010024:0.005564:0.004989:0.010009:0.009525:0.009480:0.009601:0.013879:0.009525:0.004989:0.004823:0.008920:0.009525:0.004989:0.010054:0.004248:0.008890:0.009873:0.004989:0.009601:0.004445:0.004989:0.009480:0.008920:0.009601:0.002721:0.009480:0.009525:0.004989:0.004445:0.009601:0.004248:0.004989:0.004823:0.008920:0.009525:0.005564:0.009525:0.004989:0.002721:0.008920:0.010054:0.002721:0.005020
cations and cholestyramine is now rarely prescribed.:@0.076190:0.303893:0.444596:0.303893:0.444596:0.288110:0.076190:0.288110:0.009480:0.010024:0.004823:0.002721:0.009601:0.008920:0.005564:0.003886:0.010024:0.008920:0.010054:0.003886:0.009480:0.008920:0.009601:0.002721:0.009525:0.005564:0.004823:0.007801:0.004248:0.010024:0.013879:0.002721:0.008920:0.009525:0.003886:0.002721:0.005564:0.003886:0.008920:0.009601:0.012262:0.003886:0.004248:0.010024:0.004248:0.009525:0.002721:0.007801:0.003886:0.010009:0.004248:0.009525:0.005564:0.009480:0.004248:0.002721:0.010009:0.009525:0.010054:0.004188
fibrates:@0.076190:0.335261:0.139018:0.335261:0.139018:0.316930:0.076190:0.316930:0.008063:0.004032:0.011087:0.005376:0.011087:0.005040:0.010751:0.007392
Fibrates activate the peroxisome proliferator-activated :@0.076190:0.351791:0.485175:0.351791:0.485175:0.336009:0.076190:0.336009:0.007182:0.002873:0.010160:0.004400:0.010175:0.004974:0.009676:0.005715:0.007030:0.010175:0.009631:0.004974:0.002873:0.008225:0.010175:0.004974:0.009676:0.007030:0.004974:0.009071:0.009676:0.007030:0.010160:0.009676:0.004400:0.009752:0.007106:0.002873:0.005715:0.009752:0.014030:0.009676:0.007030:0.010160:0.004400:0.009752:0.002873:0.002873:0.004596:0.009676:0.004400:0.010175:0.004974:0.009752:0.004400:0.004868:0.010175:0.009631:0.004974:0.002873:0.008225:0.010175:0.004974:0.009676:0.010357:0.004188
receptor  α  (PPAR-α)  and  thus  influence  multiple  path:@0.076190:0.366154:0.476104:0.366154:0.476104:0.350371:0.076190:0.350371:0.004400:0.009676:0.009631:0.009676:0.010160:0.004974:0.009752:0.004400:0.004188:0.002661:0.010175:0.004188:0.002661:0.005428:0.008799:0.008799:0.011037:0.009026:0.004868:0.010175:0.005428:0.004188:0.002661:0.010175:0.009071:0.010205:0.004188:0.002676:0.004974:0.009071:0.009041:0.005715:0.004188:0.002676:0.002873:0.009071:0.003591:0.003591:0.009041:0.009676:0.009071:0.009631:0.009676:0.004188:0.002676:0.014030:0.009041:0.002873:0.004974:0.002873:0.010160:0.002873:0.009676:0.004188:0.002676:0.010160:0.010175:0.004974:0.009223
-:@0.475953:0.366154:0.480972:0.366154:0.480972:0.350371:0.475953:0.350371:0.005020
ways in lipoprotein metabolism. Fibrates reduce tri-:@0.076190:0.380516:0.480972:0.380516:0.480972:0.364734:0.076190:0.364734:0.012413:0.010175:0.007953:0.005715:0.011112:0.002873:0.009071:0.011112:0.002873:0.002873:0.010160:0.009752:0.010160:0.004400:0.009752:0.004974:0.009676:0.002873:0.009071:0.011112:0.014030:0.009676:0.004974:0.010175:0.010160:0.009752:0.002873:0.002873:0.005715:0.014030:0.004037:0.011112:0.007182:0.002873:0.010160:0.004400:0.010175:0.004974:0.009676:0.005715:0.011112:0.004400:0.009676:0.010205:0.009041:0.009631:0.009676:0.011112:0.004974:0.004400:0.002873:0.005020
glycerides and increase HDLC. They may reduce LDLC :@0.076190:0.394879:0.485100:0.394879:0.485100:0.379096:0.076190:0.379096:0.010024:0.002873:0.007953:0.009631:0.009676:0.004400:0.002873:0.010205:0.009676:0.005715:0.005987:0.010175:0.009071:0.010205:0.005987:0.002873:0.009071:0.009631:0.004400:0.009676:0.010175:0.005715:0.009676:0.005987:0.010175:0.011097:0.006834:0.012141:0.004037:0.005987:0.006290:0.009071:0.009676:0.007953:0.005987:0.014030:0.010175:0.007953:0.005987:0.004400:0.009676:0.010205:0.009041:0.009631:0.009676:0.005987:0.006834:0.011097:0.006834:0.012292:0.004188
modestly. They are indicated for patients with severe :@0.076190:0.409241:0.485191:0.409241:0.485191:0.393459:0.076190:0.393459:0.014030:0.009752:0.010205:0.009676:0.005715:0.004974:0.002873:0.007953:0.004037:0.007922:0.006290:0.009071:0.009676:0.007953:0.007922:0.010175:0.004400:0.009676:0.007922:0.002873:0.009071:0.010205:0.002873:0.009631:0.010175:0.004974:0.009676:0.010205:0.007922:0.004596:0.009752:0.004400:0.007922:0.010160:0.010175:0.004974:0.002873:0.009676:0.009071:0.004974:0.005715:0.007922:0.012413:0.002873:0.004974:0.009071:0.007922:0.005715:0.009676:0.008225:0.009676:0.004400:0.009827:0.004188
hypertriglyceridaemia and in some patients with mixed :@0.076190:0.423604:0.485115:0.423604:0.485115:0.407821:0.076190:0.407821:0.009071:0.007953:0.010160:0.009676:0.004400:0.004974:0.004400:0.002873:0.010024:0.002873:0.007953:0.009631:0.009676:0.004400:0.002873:0.010205:0.010175:0.009676:0.014030:0.002873:0.010175:0.005851:0.010175:0.009071:0.010205:0.005851:0.002873:0.009071:0.005851:0.005715:0.009752:0.014030:0.009676:0.005851:0.010160:0.010175:0.004974:0.002873:0.009676:0.009071:0.004974:0.005715:0.005851:0.012413:0.002873:0.004974:0.009071:0.005851:0.014030:0.002873:0.007106:0.009676:0.010357:0.004188
hyperlipidaemia where both cholesterol and triglycerides :@0.076190:0.437967:0.485130:0.437967:0.485130:0.422184:0.076190:0.422184:0.009071:0.007953:0.010160:0.009676:0.004400:0.002873:0.002873:0.010160:0.002873:0.010205:0.010175:0.009676:0.014030:0.002873:0.010175:0.003024:0.012413:0.009071:0.009676:0.004400:0.009676:0.003024:0.010160:0.009752:0.004974:0.009071:0.003024:0.009631:0.009071:0.009752:0.002873:0.009676:0.005715:0.004974:0.009676:0.004400:0.009752:0.002873:0.003024:0.010175:0.009071:0.010205:0.003024:0.004974:0.004400:0.002873:0.010024:0.002873:0.007953:0.009631:0.009676:0.004400:0.002873:0.010205:0.009676:0.005866:0.004188
are elevated. Fibrates are often prescribed in combina-:@0.076190:0.452329:0.480957:0.452329:0.480957:0.436546:0.076190:0.436546:0.010175:0.004400:0.009676:0.004853:0.009676:0.002873:0.009676:0.008225:0.010175:0.004974:0.009676:0.010205:0.004037:0.004853:0.007182:0.002873:0.010160:0.004400:0.010175:0.004974:0.009676:0.005715:0.004853:0.010175:0.004400:0.009676:0.004853:0.009752:0.004596:0.004974:0.009676:0.009071:0.004853:0.010160:0.004400:0.009676:0.005715:0.009631:0.004400:0.002873:0.010160:0.009676:0.010205:0.004853:0.002873:0.009071:0.004853:0.009631:0.009752:0.014030:0.010160:0.002873:0.009071:0.010175:0.005020
tion with statins for the latter indication, but combination :@0.076190:0.466692:0.485145:0.466692:0.485145:0.450909:0.076190:0.450909:0.004974:0.002873:0.009752:0.009071:0.004188:0.012413:0.002873:0.004974:0.009071:0.004188:0.005715:0.004974:0.010175:0.004974:0.002873:0.009071:0.005715:0.004188:0.004596:0.009752:0.004400:0.004188:0.004974:0.009071:0.009676:0.004188:0.002873:0.010175:0.004974:0.004974:0.009676:0.004400:0.004188:0.002873:0.009071:0.010205:0.002873:0.009631:0.010175:0.004974:0.002873:0.009752:0.009071:0.004037:0.004188:0.010160:0.009041:0.004974:0.004188:0.009631:0.009752:0.014030:0.010160:0.002873:0.009071:0.010175:0.004974:0.002873:0.009752:0.009223:0.004188
therapy is associated with a higher risk of side effects :@0.076190:0.481054:0.485100:0.481054:0.485100:0.465272:0.076190:0.465272:0.004974:0.009071:0.009676:0.004400:0.010175:0.010160:0.007953:0.007106:0.002873:0.005715:0.007106:0.010175:0.005715:0.005715:0.009752:0.009631:0.002873:0.010175:0.004974:0.009676:0.010205:0.007106:0.012413:0.002873:0.004974:0.009071:0.007106:0.010175:0.007106:0.009071:0.002873:0.010024:0.009071:0.009676:0.004400:0.007106:0.004400:0.002873:0.005715:0.007439:0.007106:0.009752:0.004596:0.007106:0.005715:0.002873:0.010205:0.009676:0.007106:0.009676:0.004596:0.004596:0.009676:0.009631:0.004974:0.005866:0.004188
(myopathy) and should be initiated and monitored by :@0.076190:0.495417:0.485100:0.495417:0.485100:0.479634:0.076190:0.479634:0.005428:0.014030:0.007953:0.009752:0.010160:0.010175:0.004974:0.009071:0.007953:0.005428:0.006244:0.010175:0.009071:0.010205:0.006244:0.005715:0.009071:0.009752:0.009041:0.002873:0.010205:0.006244:0.010160:0.009676:0.006244:0.002873:0.009071:0.002873:0.004974:0.002873:0.010175:0.004974:0.009676:0.010205:0.006244:0.010175:0.009071:0.010205:0.006244:0.014030:0.009752:0.009071:0.002873:0.004974:0.009752:0.004400:0.009676:0.010205:0.006244:0.010160:0.008104:0.004188
specialists. Renal clearance is important in fibrate meta:@0.076190:0.509779:0.476089:0.509779:0.476089:0.493997:0.076190:0.493997:0.005715:0.010160:0.009676:0.009631:0.002873:0.010175:0.002873:0.002873:0.005715:0.004974:0.005715:0.004037:0.004687:0.009026:0.009676:0.009071:0.010175:0.002873:0.004687:0.009631:0.002873:0.009676:0.010175:0.004400:0.010175:0.009071:0.009631:0.009676:0.004687:0.002873:0.005715:0.004687:0.002873:0.014030:0.010160:0.009752:0.004400:0.004974:0.010175:0.009071:0.004974:0.004687:0.002873:0.009071:0.004687:0.003606:0.003606:0.010160:0.004400:0.010175:0.004974:0.009676:0.004687:0.014030:0.009676:0.004974:0.010326
-:@0.475938:0.509779:0.480957:0.509779:0.480957:0.493997:0.475938:0.493997:0.005020
bolism  and great care must be  taken  in  patients  with :@0.076190:0.524142:0.485130:0.524142:0.485130:0.508359:0.076190:0.508359:0.010160:0.009752:0.002873:0.002873:0.005715:0.014030:0.004188:0.002782:0.010175:0.009071:0.010205:0.006985:0.010024:0.004400:0.009676:0.010175:0.004974:0.006985:0.009631:0.010175:0.004400:0.009676:0.006985:0.014030:0.009041:0.005715:0.004974:0.006985:0.010160:0.009676:0.004188:0.002782:0.004974:0.010175:0.007439:0.009676:0.009071:0.004188:0.002782:0.002873:0.009071:0.004188:0.002782:0.010160:0.010175:0.004974:0.002873:0.009676:0.009071:0.004974:0.005715:0.004188:0.002782:0.012413:0.002873:0.004974:0.009223:0.004188
impaired renal function. The currently available fibrates :@0.076190:0.538504:0.485115:0.538504:0.485115:0.522722:0.076190:0.522722:0.002873:0.014030:0.010160:0.010175:0.002873:0.004400:0.009676:0.010205:0.005730:0.004400:0.009676:0.009071:0.010175:0.002873:0.005730:0.004596:0.009041:0.009071:0.009631:0.004974:0.002873:0.009752:0.009071:0.004037:0.005730:0.006290:0.009071:0.009676:0.005730:0.009631:0.009041:0.004400:0.004400:0.009676:0.009071:0.004974:0.002873:0.007953:0.005730:0.010175:0.008225:0.010175:0.002873:0.002873:0.010175:0.010160:0.002873:0.009676:0.005730:0.003606:0.003606:0.010160:0.004400:0.010175:0.004974:0.009676:0.005866:0.004188
are bezafibrate, fenofibrate and gemfibrozil. Gemfibrozil :@0.076190:0.552867:0.485191:0.552867:0.485191:0.537084:0.076190:0.537084:0.010175:0.004400:0.009676:0.004551:0.010160:0.009676:0.006274:0.010175:0.003606:0.003606:0.010160:0.004400:0.010175:0.004974:0.009676:0.004037:0.004551:0.004596:0.009676:0.009071:0.009752:0.003606:0.003606:0.010160:0.004400:0.010175:0.004974:0.009676:0.004551:0.010175:0.009071:0.010205:0.004551:0.010024:0.009676:0.014030:0.003606:0.003606:0.010160:0.004400:0.009752:0.006274:0.002873:0.002873:0.004037:0.004551:0.013033:0.009676:0.014030:0.003606:0.003606:0.010160:0.004400:0.009752:0.006274:0.002873:0.003024:0.004188
should not be prescribed in combination with statins due :@0.076190:0.567229:0.485100:0.567229:0.485100:0.551447:0.076190:0.551447:0.005715:0.009071:0.009752:0.009041:0.002873:0.010205:0.003916:0.009071:0.009752:0.004974:0.003916:0.010160:0.009676:0.003916:0.010160:0.004400:0.009676:0.005715:0.009631:0.004400:0.002873:0.010160:0.009676:0.010205:0.003916:0.002873:0.009071:0.003916:0.009631:0.009752:0.014030:0.010160:0.002873:0.009071:0.010175:0.004974:0.002873:0.009752:0.009071:0.003916:0.012413:0.002873:0.004974:0.009071:0.003916:0.005715:0.004974:0.010175:0.004974:0.002873:0.009071:0.005715:0.003916:0.010205:0.009041:0.009827:0.004188
to a higher risk of interactions. Fenofibrate has shown in:@0.076190:0.581592:0.476149:0.581592:0.476149:0.565809:0.076190:0.565809:0.004974:0.009752:0.004732:0.010175:0.004732:0.009071:0.002873:0.010024:0.009071:0.009676:0.004400:0.004732:0.004400:0.002873:0.005715:0.007439:0.004732:0.009752:0.004596:0.004732:0.002873:0.009071:0.004974:0.009676:0.004400:0.010175:0.009631:0.004974:0.002873:0.009752:0.009071:0.005715:0.004037:0.004732:0.007182:0.009676:0.009071:0.009752:0.003606:0.003606:0.010160:0.004400:0.010175:0.004974:0.009676:0.004732:0.009071:0.010175:0.005715:0.004732:0.005715:0.009071:0.009752:0.012413:0.009071:0.004732:0.002873:0.009223
-:@0.475998:0.581592:0.481018:0.581592:0.481018:0.565809:0.475998:0.565809:0.005020
triguing benefits on diabetic microvascular disease in a :@0.076190:0.595954:0.485175:0.595954:0.485175:0.580172:0.076190:0.580172:0.004974:0.004400:0.002873:0.010024:0.009041:0.002873:0.009071:0.010024:0.005488:0.010160:0.009676:0.009071:0.009676:0.003606:0.003606:0.004974:0.005715:0.005488:0.009752:0.009071:0.005488:0.010205:0.002873:0.010175:0.010160:0.009676:0.004974:0.002873:0.009631:0.005488:0.014030:0.002873:0.009631:0.004400:0.009752:0.008225:0.010175:0.005715:0.009631:0.009041:0.002873:0.010175:0.004400:0.005488:0.010205:0.002873:0.005715:0.009676:0.010175:0.005715:0.009676:0.005488:0.002873:0.009071:0.005488:0.010326:0.004188
recent study.:@0.076190:0.610317:0.170866:0.610317:0.170866:0.594534:0.076190:0.594534:0.004400:0.009676:0.009631:0.009676:0.009071:0.004974:0.005171:0.005715:0.004974:0.009041:0.010205:0.007953:0.004188
3:@0.170698:0.604941:0.175556:0.604941:0.175556:0.595787:0.170698:0.595787:0.004858
  Routine addition of fenofibrate to simva:@0.175470:0.610239:0.476142:0.610239:0.476142:0.594457:0.175470:0.594457:0.005171:0.005171:0.009026:0.009752:0.009041:0.004974:0.002873:0.009071:0.009676:0.005171:0.010175:0.010205:0.010205:0.002873:0.004974:0.002873:0.009752:0.009071:0.005171:0.009752:0.004596:0.005171:0.004596:0.009676:0.009071:0.009752:0.003606:0.003606:0.010160:0.004400:0.010175:0.004974:0.009676:0.005171:0.004974:0.009752:0.005171:0.005715:0.002873:0.014030:0.008225:0.010326
-:@0.475991:0.610239:0.481011:0.610239:0.481011:0.594457:0.475991:0.594457:0.005020
statin in another study of diabetics with very high cardio-:@0.076183:0.624602:0.480965:0.624602:0.480965:0.608819:0.076183:0.608819:0.005715:0.004974:0.010175:0.004974:0.002873:0.009071:0.004082:0.002873:0.009071:0.004082:0.010175:0.009071:0.009752:0.004974:0.009071:0.009676:0.004400:0.004082:0.005715:0.004974:0.009041:0.010205:0.007953:0.004082:0.009752:0.004596:0.004082:0.010205:0.002873:0.010175:0.010160:0.009676:0.004974:0.002873:0.009631:0.005715:0.004082:0.012413:0.002873:0.004974:0.009071:0.004082:0.008225:0.009676:0.004400:0.007953:0.004082:0.009071:0.002873:0.010024:0.009071:0.004082:0.009631:0.010175:0.004400:0.010205:0.002873:0.009752:0.005020
vascular risk did not improve cardiovascular outcomes, :@0.076183:0.638964:0.485093:0.638964:0.485093:0.623182:0.076183:0.623182:0.008225:0.010175:0.005715:0.009631:0.009041:0.002873:0.010175:0.004400:0.005639:0.004400:0.002873:0.005715:0.007439:0.005639:0.010205:0.002873:0.010205:0.005639:0.009071:0.009752:0.004974:0.005639:0.002873:0.014030:0.010160:0.004400:0.009752:0.008225:0.009676:0.005639:0.009631:0.010175:0.004400:0.010205:0.002873:0.009752:0.008225:0.010175:0.005715:0.009631:0.009041:0.002873:0.010175:0.004400:0.005639:0.009752:0.009041:0.004974:0.009631:0.009752:0.014030:0.009676:0.005715:0.004188:0.004188
except possibly in the subgroup with the highest triglycer-:@0.076183:0.653327:0.480905:0.653327:0.480905:0.637544:0.076183:0.637544:0.009676:0.007106:0.009631:0.009676:0.010160:0.004974:0.003508:0.010160:0.009752:0.005715:0.005715:0.002873:0.010160:0.002873:0.007953:0.003508:0.002873:0.009071:0.003508:0.004974:0.009071:0.009676:0.003508:0.005715:0.009041:0.010160:0.010024:0.004400:0.009752:0.009041:0.010160:0.003508:0.012413:0.002873:0.004974:0.009071:0.003508:0.004974:0.009071:0.009676:0.003508:0.009071:0.002873:0.010024:0.009071:0.009676:0.005715:0.004974:0.003508:0.004974:0.004400:0.002873:0.010024:0.002873:0.007953:0.009631:0.009676:0.004400:0.005020
ides and lowest HDLC.:@0.076183:0.667690:0.236052:0.667690:0.236052:0.651907:0.076183:0.651907:0.002873:0.010205:0.009676:0.005715:0.004037:0.010175:0.009071:0.010205:0.004037:0.002873:0.009752:0.012413:0.009676:0.005715:0.004974:0.004037:0.010175:0.011097:0.006834:0.012141:0.004188
4:@0.235907:0.662374:0.240765:0.662374:0.240765:0.653220:0.235907:0.653220:0.004858
nicotinic acid:@0.076190:0.699101:0.189751:0.699101:0.189751:0.680770:0.076190:0.680770:0.012431:0.004032:0.010751:0.010751:0.005040:0.004032:0.010079:0.004032:0.010751:0.004704:0.011087:0.010751:0.004032:0.011087
Nicotinic acid (or niacin) is a B-group vitamin that influ:@0.076190:0.715631:0.475938:0.715631:0.475938:0.699848:0.076190:0.699848:0.011188:0.003024:0.009782:0.009903:0.005125:0.003024:0.009223:0.003024:0.009782:0.004778:0.010326:0.009782:0.003024:0.010357:0.004793:0.005579:0.009903:0.004551:0.004778:0.009223:0.003024:0.010326:0.009782:0.003024:0.009223:0.005579:0.004793:0.003024:0.005866:0.004793:0.010326:0.004793:0.008678:0.005020:0.010175:0.004551:0.009903:0.009192:0.010311:0.004778:0.008376:0.003024:0.005125:0.010326:0.014182:0.003024:0.009223:0.004793:0.005125:0.009223:0.010326:0.005125:0.004778:0.003024:0.009223:0.003666:0.003666:0.009192
-:@0.475938:0.715631:0.480957:0.715631:0.480957:0.699848:0.475938:0.699848:0.005020
ences lipid metabolism in pharmacological dosages. It :@0.076190:0.729994:0.485145:0.729994:0.485145:0.714211:0.076190:0.714211:0.009827:0.009223:0.009782:0.009827:0.005866:0.004929:0.003024:0.003024:0.010311:0.003024:0.010357:0.004929:0.014182:0.009827:0.005125:0.010326:0.010311:0.009903:0.003024:0.003024:0.005866:0.014182:0.004929:0.003024:0.009223:0.004929:0.010311:0.009223:0.010326:0.004551:0.014182:0.010326:0.009782:0.009903:0.003024:0.009903:0.010175:0.003024:0.009782:0.010326:0.003024:0.004929:0.010357:0.009903:0.005866:0.010326:0.010175:0.009827:0.005866:0.004188:0.004929:0.003417:0.005125:0.004188
decreases triglycerides, increases HDLC and modestly :@0.076190:0.744356:0.485145:0.744356:0.485145:0.728574:0.076190:0.728574:0.010357:0.009827:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.005866:0.006335:0.005125:0.004551:0.003024:0.010175:0.003024:0.008104:0.009782:0.009827:0.004551:0.003024:0.010357:0.009827:0.005866:0.004188:0.006335:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.005866:0.006335:0.010326:0.011249:0.006985:0.012292:0.006335:0.010326:0.009223:0.010357:0.006335:0.014182:0.009903:0.010357:0.009827:0.005866:0.005125:0.003024:0.008104:0.004188
lowers LDLC. Flushing is a problematic and frequent side :@0.076190:0.758719:0.485130:0.758719:0.485130:0.742936:0.076190:0.742936:0.003024:0.009903:0.012564:0.009827:0.004551:0.005866:0.003613:0.006985:0.011249:0.006985:0.012292:0.004188:0.003613:0.007333:0.003024:0.009192:0.005866:0.009223:0.003024:0.009223:0.010175:0.003613:0.003024:0.005866:0.003613:0.010326:0.003613:0.010311:0.004551:0.009903:0.010311:0.003024:0.009827:0.014182:0.010326:0.005125:0.003024:0.009782:0.003613:0.010326:0.009223:0.010357:0.003613:0.004747:0.004551:0.009827:0.010311:0.009192:0.009827:0.009223:0.005125:0.003598:0.005866:0.003024:0.010357:0.009827:0.004188
effect.  Extended-release  preparations  are  associated :@0.076190:0.773081:0.485115:0.773081:0.485115:0.757299:0.076190:0.757299:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.004188:0.004188:0.003235:0.008104:0.007257:0.005125:0.009827:0.009223:0.010357:0.009827:0.010357:0.005020:0.004551:0.009827:0.003024:0.009827:0.010326:0.005866:0.009827:0.004188:0.003235:0.010311:0.004551:0.009827:0.010311:0.010326:0.004551:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.003235:0.010326:0.004551:0.009827:0.004188:0.003235:0.010326:0.005866:0.005866:0.009903:0.009782:0.003024:0.010326:0.005125:0.009827:0.010357:0.004188
with less flushing. Flushing is also reduced by co-admin:@0.076190:0.787444:0.475907:0.787444:0.475907:0.771661:0.076190:0.771661:0.012564:0.003024:0.005125:0.009223:0.004717:0.003024:0.009827:0.005866:0.005866:0.004732:0.003666:0.003666:0.009192:0.005866:0.009223:0.003024:0.009223:0.010175:0.004188:0.004717:0.007333:0.003024:0.009192:0.005866:0.009223:0.003024:0.009223:0.010175:0.004717:0.003024:0.005866:0.004732:0.010326:0.003024:0.005866:0.009903:0.004717:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.010357:0.004717:0.010311:0.008104:0.004732:0.009782:0.009903:0.005020:0.010326:0.010357:0.014182:0.003024:0.009223
-:@0.475907:0.787444:0.480927:0.787444:0.480927:0.771661:0.475907:0.771661:0.005020
istering nicotinic acid with a specific prostaglandin D2 :@0.076190:0.801806:0.485130:0.801806:0.485130:0.786024:0.076190:0.786024:0.003024:0.005866:0.005125:0.009827:0.004551:0.003024:0.009223:0.010175:0.005866:0.009223:0.003024:0.009782:0.009903:0.005125:0.003024:0.009223:0.003024:0.009782:0.005866:0.010326:0.009782:0.003024:0.010357:0.005866:0.012564:0.003024:0.005125:0.009223:0.005866:0.010326:0.005866:0.005866:0.010311:0.009827:0.009782:0.003024:0.003681:0.003681:0.009782:0.005866:0.010311:0.004551:0.009903:0.005866:0.005125:0.010326:0.010175:0.003024:0.010326:0.009223:0.010357:0.003024:0.009223:0.005866:0.011249:0.008376:0.004188
receptor subtype 1 blocker (laropiprant).  There is cur-:@0.076190:0.816169:0.480957:0.816139:0.480957:0.800356:0.076190:0.800386:0.004551:0.009827:0.009782:0.009827:0.010311:0.005125:0.009903:0.004551:0.005791:0.005866:0.009192:0.010311:0.005125:0.008104:0.010311:0.009827:0.005806:0.008376:0.005806:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005791:0.005579:0.003024:0.010326:0.004551:0.009903:0.010311:0.003024:0.010311:0.004551:0.010326:0.009223:0.005125:0.005579:0.004188:0.004868:0.005806:0.006441:0.009223:0.009827:0.004551:0.009827:0.005791:0.003024:0.005866:0.005806:0.009782:0.009192:0.004551:-0.214499
5:@0.381391:0.810840:0.386249:0.810840:0.386249:0.801686:0.381391:0.801686:0.004858
rently renewed interest in this old drug as it has multi-:@0.076190:0.830501:0.480957:0.830501:0.480957:0.814719:0.076190:0.814719:0.004551:0.009827:0.009223:0.005125:0.003024:0.008104:0.006380:0.004551:0.009827:0.009223:0.009827:0.012564:0.009827:0.010357:0.006380:0.003024:0.009223:0.005125:0.009827:0.004551:0.009827:0.005866:0.005125:0.006380:0.003024:0.009223:0.006380:0.005125:0.009223:0.003024:0.005866:0.006380:0.009903:0.003024:0.010357:0.006380:0.010357:0.004551:0.009192:0.010175:0.006380:0.010326:0.005866:0.006380:0.003024:0.005125:0.006380:0.009223:0.010326:0.005866:0.006380:0.014182:0.009192:0.003024:0.005125:0.003024:0.005020
ple beneficial effects on the lipid profile and newer for:@0.076190:0.844864:0.475937:0.844864:0.475937:0.829081:0.076190:0.829081:0.010311:0.003024:0.009827:0.004536:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.009782:0.003024:0.010326:0.003024:0.004536:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.004536:0.009903:0.009223:0.004536:0.005125:0.009223:0.009827:0.004536:0.003024:0.003024:0.010311:0.003024:0.010357:0.004551:0.010311:0.004551:0.009903:0.003681:0.003681:0.003024:0.009827:0.004536:0.010326:0.009223:0.010357:0.004536:0.009223:0.009827:0.012564:0.009827:0.004551:0.004536:0.004747:0.009903:0.004551
-:@0.475937:0.844864:0.480957:0.844864:0.480957:0.829081:0.475937:0.829081:0.005020
mulations are better tolerated. In a recently published, :@0.076190:0.859226:0.485130:0.859226:0.485130:0.843444:0.076190:0.843444:0.014182:0.009192:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.005065:0.010326:0.004551:0.009827:0.005065:0.010311:0.009827:0.005125:0.005125:0.009827:0.004551:0.005050:0.005125:0.009903:0.003024:0.009827:0.004551:0.010326:0.005125:0.009827:0.010357:0.004188:0.005050:0.003417:0.009223:0.005065:0.010326:0.005065:0.004551:0.009827:0.009782:0.009827:0.009223:0.005125:0.003024:0.008104:0.005050:0.010311:0.009192:0.010311:0.003024:0.003024:0.005866:0.009223:0.009827:0.010357:0.004188:0.004188
relatively small study, niacin therapy did not  improve :@0.076190:0.873589:0.485130:0.873589:0.485130:0.857806:0.076190:0.857806:0.004551:0.009827:0.003024:0.010326:0.005125:0.003024:0.008376:0.009827:0.003024:0.008104:0.007151:0.005866:0.014182:0.010326:0.003024:0.003039:0.007151:0.005866:0.005125:0.009192:0.010357:0.008104:0.004188:0.007151:0.009223:0.003024:0.010326:0.009782:0.003024:0.009223:0.007151:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.007151:0.010357:0.003024:0.010357:0.007151:0.009223:0.009903:0.005125:0.004188:0.002948:0.003024:0.014182:0.010311:0.004551:0.009903:0.008376:0.009827:0.004188
cardiovascular outcomes when added to intensive sta-:@0.076190:0.887951:0.480942:0.887951:0.480942:0.872169:0.076190:0.872169:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004112:0.009903:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.005866:0.004097:0.012564:0.009223:0.009827:0.009223:0.004112:0.010326:0.010357:0.010357:0.009827:0.010357:0.004112:0.005125:0.009903:0.004097:0.003024:0.009223:0.005125:0.009827:0.009223:0.005866:0.003024:0.008376:0.009827:0.004112:0.005866:0.005125:0.010326:0.005020
tin therapy and the results of a larger trial are awaited to :@0.076190:0.902314:0.485130:0.902314:0.485130:0.886531:0.076190:0.886531:0.005125:0.003024:0.009223:0.003417:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.003432:0.010326:0.009223:0.010357:0.003417:0.005125:0.009223:0.009827:0.003417:0.004551:0.009827:0.005866:0.009192:0.003024:0.005125:0.005866:0.003417:0.009903:0.004747:0.003417:0.010326:0.003417:0.003024:0.010326:0.004551:0.010175:0.009827:0.004551:0.003417:0.005125:0.004551:0.003024:0.010326:0.003024:0.003417:0.010326:0.004551:0.009827:0.003417:0.010326:0.012564:0.010326:0.003024:0.005125:0.009827:0.010357:0.003432:0.005125:0.009903:0.004188
clarify the role of niacin in cardiovascular risk reduction.  :@0.076190:0.916677:0.485140:0.916646:0.485140:0.900864:0.076190:0.900894:0.009782:0.003024:0.010326:0.004551:0.003024:0.004747:0.008104:0.003477:0.005125:0.009223:0.009827:0.003462:0.004551:0.009903:0.003024:0.009827:0.003462:0.009903:0.004747:0.003477:0.009223:0.003024:0.010326:0.009782:0.003024:0.009223:0.003477:0.003024:0.009223:0.003477:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.003477:0.004551:0.003024:0.005866:0.007590:0.003477:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.004848:-0.351131
6:@0.476092:0.911348:0.480950:0.911348:0.480950:0.902194:0.476092:0.902194:0.004858
Although niacin can increase glucose, this is usually not :@0.076185:0.931009:0.485140:0.931009:0.485140:0.915226:0.076185:0.915226:0.011188:0.003024:0.005125:0.009223:0.009903:0.009192:0.010175:0.009223:0.004279:0.009223:0.003024:0.010326:0.009782:0.003024:0.009223:0.004294:0.009782:0.010326:0.009223:0.004279:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.004279:0.010175:0.003024:0.009192:0.009782:0.009903:0.005866:0.009827:0.004188:0.004279:0.005125:0.009223:0.003024:0.005866:0.004294:0.003024:0.005866:0.004294:0.009192:0.005866:0.009192:0.010326:0.003024:0.003024:0.008104:0.004294:0.009223:0.009903:0.005125:0.004188
clinically problematic.:@0.076185:0.945371:0.237263:0.945371:0.237263:0.929589:0.076185:0.929589:0.009782:0.003024:0.003024:0.009223:0.003024:0.009782:0.010326:0.003024:0.003024:0.008104:0.004188:0.010311:0.004551:0.009903:0.010311:0.003024:0.009827:0.014182:0.010326:0.005125:0.003024:0.009782:0.004188
7:@0.237281:0.940064:0.242139:0.940064:0.242139:0.930910:0.237281:0.930910:0.004858
COnClusiOn:@0.519047:0.087643:0.641007:0.087643:0.641007:0.067478:0.519047:0.067478:0.014413:0.015522:0.013674:0.014413:0.008131:0.011826:0.009609:0.005174:0.015522:0.013674
With our current armamentarium of lipid-lowering medi-:@0.519047:0.103532:0.923784:0.103532:0.923784:0.087750:0.519047:0.087750:0.014363:0.002873:0.004974:0.009071:0.005156:0.009752:0.009041:0.004400:0.005156:0.009631:0.009041:0.004400:0.004400:0.009676:0.009071:0.004974:0.005156:0.010175:0.004400:0.014030:0.010175:0.014030:0.009676:0.009071:0.004974:0.010175:0.004400:0.002873:0.009041:0.014030:0.005156:0.009752:0.004596:0.005156:0.002873:0.002873:0.010160:0.002873:0.010205:0.004868:0.002873:0.009752:0.012413:0.009676:0.004400:0.002873:0.009071:0.010024:0.005156:0.014030:0.009676:0.010205:0.002873:0.005020
cation, it is possible to manage dyslipidaemia safely and :@0.519047:0.117641:0.927987:0.117641:0.927987:0.101858:0.519047:0.101858:0.009631:0.010175:0.004974:0.002873:0.009752:0.009071:0.004037:0.004067:0.002873:0.004974:0.004082:0.002873:0.005715:0.004082:0.010160:0.009752:0.005715:0.005715:0.002873:0.010160:0.002873:0.009676:0.004082:0.004974:0.009752:0.004067:0.014030:0.010175:0.009071:0.010175:0.010024:0.009676:0.004082:0.010205:0.007953:0.005715:0.002873:0.002873:0.010160:0.002873:0.010205:0.010175:0.009676:0.014030:0.002873:0.010175:0.004082:0.005715:0.010175:0.004596:0.009676:0.002873:0.007953:0.004082:0.010175:0.009071:0.010357:0.004188
effectively in the vast majority of patients. Lipid-modifying :@0.519047:0.131749:0.928017:0.131749:0.928017:0.115967:0.519047:0.115967:0.009676:0.004596:0.004596:0.009676:0.009631:0.004974:0.002873:0.008225:0.009676:0.002873:0.007953:0.003266:0.002873:0.009071:0.003266:0.004974:0.009071:0.009676:0.003266:0.008225:0.010175:0.005715:0.004974:0.003266:0.014030:0.010175:0.002918:0.009752:0.004400:0.002873:0.004974:0.007953:0.003266:0.009752:0.004596:0.003266:0.010160:0.010175:0.004974:0.002873:0.009676:0.009071:0.004974:0.005715:0.004037:0.003266:0.006834:0.002873:0.010160:0.002873:0.010205:0.004868:0.014030:0.009752:0.010205:0.002873:0.004596:0.007953:0.002873:0.009071:0.010175:0.004188
drugs only prevent a proportion of cardiovascular events :@0.519047:0.145858:0.928002:0.145858:0.928002:0.130075:0.519047:0.130075:0.010205:0.004400:0.009041:0.010024:0.005715:0.003568:0.009752:0.009071:0.002873:0.007953:0.003568:0.010160:0.004400:0.009676:0.008225:0.009676:0.009071:0.004974:0.003568:0.010175:0.003568:0.010160:0.004400:0.009752:0.010160:0.009752:0.004400:0.004974:0.002873:0.009752:0.009071:0.003568:0.009752:0.004596:0.003568:0.009631:0.010175:0.004400:0.010205:0.002873:0.009752:0.008225:0.010175:0.005715:0.009631:0.009041:0.002873:0.010175:0.004400:0.003568:0.009676:0.008225:0.009676:0.009071:0.004974:0.005866:0.004188
and research into further “anti-atherosclerotic” drugs is :@0.519047:0.159966:0.927987:0.159966:0.927987:0.144184:0.519047:0.144184:0.010175:0.009071:0.010205:0.006244:0.004400:0.009676:0.005715:0.009676:0.010175:0.004400:0.009631:0.009071:0.006244:0.002873:0.009071:0.004974:0.009752:0.006244:0.004596:0.009041:0.004400:0.004974:0.009071:0.009676:0.004400:0.006244:0.007439:0.010175:0.009071:0.004974:0.002873:0.004868:0.010175:0.004974:0.009071:0.009676:0.004400:0.009752:0.005715:0.009631:0.002873:0.009676:0.004400:0.009752:0.004974:0.002873:0.009631:0.007166:0.006244:0.010205:0.004400:0.009041:0.010024:0.005715:0.006244:0.002873:0.005866:0.004188
ongoing. The bigger challenge is, however, implement-:@0.519047:0.174075:0.923829:0.174075:0.923829:0.158292:0.519047:0.158292:0.009752:0.009071:0.010024:0.009752:0.002873:0.009071:0.010024:0.004037:0.005443:0.006290:0.009071:0.009676:0.005443:0.010160:0.002873:0.010024:0.010024:0.009676:0.004400:0.005443:0.009631:0.009071:0.010175:0.002873:0.002873:0.009676:0.009071:0.010024:0.009676:0.005443:0.002873:0.005715:0.004037:0.005443:0.009071:0.009752:0.012413:0.009676:0.008225:0.009676:0.004400:0.004037:0.005443:0.002873:0.014030:0.010160:0.002873:0.009676:0.014030:0.009676:0.009071:0.004974:0.005020
ing the evidence we currently have: making these drugs :@0.519047:0.188183:0.928047:0.188183:0.928047:0.172401:0.519047:0.172401:0.002873:0.009071:0.010024:0.004067:0.004974:0.009071:0.009676:0.004067:0.009676:0.008225:0.002873:0.010205:0.009676:0.009071:0.009631:0.009676:0.004067:0.012413:0.009676:0.004067:0.009631:0.009041:0.004400:0.004400:0.009676:0.009071:0.004974:0.002873:0.007953:0.004067:0.009071:0.010175:0.008225:0.009676:0.004037:0.004067:0.014030:0.010175:0.007439:0.002873:0.009071:0.010024:0.004067:0.004974:0.009071:0.009676:0.005715:0.009676:0.004067:0.010205:0.004400:0.009041:0.010024:0.005866:0.004188
available and affordable to the patients who need them :@0.519047:0.202292:0.928032:0.202292:0.928032:0.186509:0.519047:0.186509:0.010175:0.008225:0.010175:0.002873:0.002873:0.010175:0.010160:0.002873:0.009676:0.003462:0.010175:0.009071:0.010205:0.003462:0.010175:0.004596:0.004596:0.009752:0.004400:0.010205:0.010175:0.010160:0.002873:0.009676:0.003462:0.004974:0.009752:0.003462:0.004974:0.009071:0.009676:0.003462:0.010160:0.010175:0.004974:0.002873:0.009676:0.009071:0.004974:0.005715:0.003462:0.012413:0.009071:0.009752:0.003462:0.009071:0.009676:0.009676:0.010205:0.003462:0.004974:0.009071:0.009676:0.014182:0.004188
and then securing long-term adherence.:@0.519047:0.216401:0.813309:0.216401:0.813309:0.200618:0.519047:0.200618:0.010175:0.009071:0.010205:0.004037:0.004974:0.009071:0.009676:0.009071:0.004037:0.005715:0.009676:0.009631:0.009041:0.004400:0.002873:0.009071:0.010024:0.004037:0.002873:0.009752:0.009071:0.010024:0.004868:0.004974:0.009676:0.004400:0.014030:0.004037:0.010175:0.010205:0.009071:0.009676:0.004400:0.009676:0.009071:0.009631:0.009676:0.004188
referenCes:@0.519047:0.249279:0.625485:0.249279:0.625485:0.229115:0.519047:0.229115:0.010718:0.009609:0.008870:0.009609:0.010718:0.009609:0.013674:0.014413:0.009609:0.009609
1. :@0.519047:0.261174:0.532076:0.261174:0.532076:0.248898:0.519047:0.248898:0.006515:0.003257:0.003257
Baigent C, Blackwell L, Emberson J, :@0.544247:0.261174:0.750763:0.261174:0.750763:0.248898:0.544247:0.248898:0.006750:0.008032:0.002352:0.007914:0.007644:0.007173:0.003986:0.004045:0.009560:0.003257:0.004045:0.006750:0.002352:0.008032:0.007608:0.005903:0.009772:0.007644:0.002352:0.002352:0.004057:0.005433:0.003257:0.004045:0.006303:0.011030:0.008020:0.007644:0.003540:0.004563:0.007702:0.007173:0.004045:0.005668:0.003257:0.003257
et al. Lancet:@0.751551:0.261174:0.824788:0.261174:0.824788:0.248898:0.751551:0.248898:0.007644:0.003986:0.004045:0.008032:0.002352:0.003257:0.004045:0.005433:0.008032:0.007173:0.007608:0.007644:0.003986
 :@0.780867:0.261174:0.784124:0.261174:0.784124:0.248898:0.780867:0.248898:0.003257
 2010; 376 (9753): :@0.824788:0.261174:0.927058:0.261174:0.927058:0.248898:0.824788:0.248898:0.004045:0.006515:0.006515:0.006515:0.006515:0.003257:0.004057:0.006515:0.006515:0.006515:0.004057:0.004339:0.006515:0.006515:0.006515:0.006515:0.004339:0.003257:0.003257
1670-168178.:@0.544247:0.272075:0.616555:0.272075:0.616555:0.259800:0.544247:0.259800:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.006515:0.006515:0.003257
2. :@0.519047:0.282977:0.532076:0.282977:0.532076:0.270701:0.519047:0.270701:0.006515:0.003257:0.003257
Egan A, Colman E. :@0.544247:0.282977:0.654067:0.282977:0.654067:0.270701:0.544247:0.270701:0.006303:0.007914:0.008032:0.007173:0.003257:0.008702:0.003257:0.003257:0.009560:0.007702:0.002352:0.011030:0.008032:0.007173:0.003257:0.006303:0.003257:0.003257
N Engl J Med. :@0.654055:0.282977:0.734959:0.282977:0.734959:0.270701:0.654055:0.270701:0.008702:0.003257:0.006303:0.007173:0.007914:0.002352:0.003257:0.005668:0.003257:0.010807:0.007644:0.008055:0.003257:0.003257
2011;365(4):285-287.:@0.734947:0.282977:0.848506:0.282977:0.848506:0.270701:0.734947:0.270701:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257
3. :@0.519047:0.293878:0.532076:0.293878:0.532076:0.281603:0.519047:0.281603:0.006515:0.003257:0.003257
Keech  A,  simes RJ,  Barter  p,  Best J,  scott  R, :@0.544247:0.293878:0.807725:0.293878:0.807725:0.281603:0.544247:0.281603:0.006950:0.007644:0.007644:0.007608:0.007173:0.003257:0.002140:0.008702:0.003257:0.003257:0.002140:0.005856:0.002352:0.011030:0.007644:0.004563:0.005409:0.007138:0.005668:0.003257:0.003257:0.002140:0.006750:0.008032:0.003540:0.003986:0.007644:0.003540:0.003257:0.002152:0.006961:0.003257:0.003257:0.002140:0.006750:0.007644:0.004563:0.003986:0.005409:0.005668:0.003257:0.003257:0.002152:0.005856:0.007608:0.007702:0.003986:0.003986:0.003257:0.002140:0.007138:0.003257:0.003257
et  al. Lancet:@0.809877:0.293878:0.885830:0.293878:0.885830:0.281603:0.809877:0.281603:0.007644:0.003986:0.003257:0.002140:0.008032:0.002352:0.003257:0.005409:0.005433:0.008032:0.007173:0.007608:0.007644:0.003986
 :@0.840545:0.293878:0.843802:0.293878:0.843802:0.281603:0.840545:0.281603:0.003257
. 2005; :@0.885830:0.293878:0.927070:0.293878:0.927070:0.281603:0.885830:0.281603:0.003257:0.005409:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257
366(9500):1849-1861.:@0.544247:0.304780:0.661064:0.304780:0.661064:0.292504:0.544247:0.292504:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.003257
4. :@0.519047:0.315681:0.532076:0.315681:0.532076:0.303406:0.519047:0.303406:0.006515:0.003257:0.003257
Ginsberg HN, Elam MB, Lovato LC, :@0.544247:0.315681:0.748164:0.315681:0.748164:0.303406:0.544247:0.303406:0.010254:0.002352:0.007173:0.004563:0.008020:0.007644:0.003540:0.007914:0.004610:0.008032:0.008702:0.003257:0.004610:0.006303:0.002352:0.008032:0.011030:0.004621:0.010807:0.006750:0.003257:0.004610:0.005433:0.007702:0.006515:0.008032:0.003986:0.007702:0.004610:0.005433:0.009560:0.003257:0.003257
et al. N Engl J Med.:@0.749517:0.315681:0.865710:0.315681:0.865710:0.303406:0.749517:0.303406:0.007644:0.003986:0.004610:0.008032:0.002352:0.003257:0.004610:0.008702:0.004610:0.006303:0.007173:0.007914:0.002352:0.004610:0.005668:0.004610:0.010807:0.007644:0.008055:0.003257
 :@0.779397:0.315681:0.782654:0.315681:0.782654:0.303406:0.779397:0.303406:0.003257
 2010; 362 :@0.865710:0.315681:0.927058:0.315681:0.927058:0.303406:0.865710:0.303406:0.004610:0.006515:0.006515:0.006515:0.006515:0.003257:0.004621:0.006515:0.006515:0.006515:0.003257
(17):1563-1574.:@0.544247:0.326583:0.628490:0.326583:0.628490:0.314307:0.544247:0.314307:0.004339:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.003257
5. :@0.519047:0.337484:0.532076:0.337484:0.532076:0.325209:0.519047:0.325209:0.006515:0.003257:0.003257
Cheng K, Wu TJ, Wu KK, sturino C, :@0.544247:0.337484:0.747447:0.337484:0.747447:0.325209:0.544247:0.325209:0.009560:0.007173:0.007644:0.007173:0.007914:0.004527:0.006950:0.003257:0.004527:0.011289:0.007150:0.004539:0.005009:0.005668:0.003257:0.004539:0.011289:0.007150:0.004539:0.006950:0.006950:0.003257:0.004527:0.005856:0.003986:0.007150:0.003540:0.002352:0.007173:0.007702:0.004527:0.009560:0.003257:0.003257
et al. Proc Natl Acad Sci USA.:@0.748729:0.337484:0.923824:0.337484:0.923824:0.325209:0.748729:0.325209:0.007644:0.003986:0.004527:0.008032:0.002352:0.003257:0.004539:0.006961:0.003540:0.007702:0.007608:0.004527:0.008702:0.008032:0.003986:0.002352:0.004539:0.008702:0.007608:0.008032:0.008055:0.004539:0.005856:0.007608:0.002352:0.004539:0.007702:0.005856:0.008702:0.003257
 :@0.923812:0.337484:0.927070:0.337484:0.927070:0.325209:0.923812:0.325209:0.003257
2006;103(17):6682-6687.:@0.544247:0.348386:0.677350:0.348386:0.677350:0.336110:0.544247:0.336110:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.003257
6. :@0.519047:0.359287:0.532076:0.359287:0.532076:0.347012:0.519047:0.347012:0.006515:0.003257:0.003257
Boden  WE,  Probstfield  JL,  Anderson  T, :@0.544247:0.359287:0.767732:0.359287:0.767732:0.347012:0.544247:0.347012:0.006750:0.007702:0.008055:0.007644:0.007173:0.003257:0.002011:0.011289:0.006303:0.003257:0.003257:0.002011:0.006961:0.003540:0.007691:0.008020:0.004563:0.003986:0.002863:0.002863:0.007644:0.002352:0.008055:0.003257:0.002011:0.005668:0.005433:0.003257:0.003257:0.002011:0.008702:0.007173:0.008055:0.007644:0.003540:0.004563:0.007702:0.007173:0.003257:0.002011:0.005009:0.003257:0.003257
et al. N Engl J Med. :@0.769731:0.359287:0.892474:0.359287:0.892474:0.347012:0.769731:0.347012:0.007644:0.003986:0.005268:0.008032:0.002352:0.003257:0.005268:0.008702:0.005268:0.006303:0.007173:0.007914:0.002352:0.005268:0.005668:0.005268:0.010807:0.007644:0.008055:0.003257:0.003257
2011; :@0.894485:0.359287:0.927058:0.359287:0.927058:0.347012:0.894485:0.347012:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257
365(24):2255-2267.:@0.544247:0.370188:0.648034:0.370188:0.648034:0.357913:0.544247:0.357913:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.003257
7. :@0.519047:0.381090:0.532076:0.381090:0.532076:0.368815:0.519047:0.368815:0.006515:0.003257:0.003257
Goldberg RB, Jacobson TA. :@0.544247:0.381090:0.703338:0.381090:0.703338:0.368815:0.544247:0.368815:0.010254:0.007702:0.002352:0.008055:0.008020:0.007644:0.003540:0.007914:0.003257:0.007138:0.006750:0.003257:0.003257:0.005668:0.008032:0.007608:0.007702:0.008020:0.004563:0.007702:0.007173:0.003257:0.005009:0.008702:0.003257:0.003257
Mayo Clin Proc.:@0.703315:0.381090:0.793179:0.381090:0.793179:0.368815:0.703315:0.368815:0.010807:0.008032:0.006303:0.007702:0.003257:0.009560:0.002352:0.002352:0.007173:0.003257:0.006961:0.003540:0.007702:0.007608:0.003257
 2008;83(4):470-4784.:@0.793167:0.381090:0.909983:0.381090:0.909983:0.368815:0.793167:0.368815:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.003257